Table 1.
Variable | Number (%) or mean (SD) [range] |
---|---|
All | 123(100) |
Female | 43 (35.0) |
Male | 80 (65.0) |
Age | 48.0 (16.8)[20–86] |
Other disease | |
Somatic | 49 (39.8) |
Psychiatric | 21 (17.1) |
Somatic and/or psychiatric | 61 (49.6) |
First symptom | |
Epilepsy | 87 (70.7) |
Other | 35 (28.5) |
Incidental finding | 1 (0.8) |
Previous epilepsy | 2 (1.6) |
Tumor location | |
Frontal | 53 (43.1) |
Temporal | 18 (14.6) |
Parietal | 11 (8.9) |
Occipital | 3 (2.4) |
Several lobes/large | 38 (30.9) |
Tumor grade | |
2 | 49 (39.8) |
3 | 19 (15.4) |
4 | 55 (44.7) |
IDH mutation | |
Yes | 53 (43.1) |
No | 62 (50.4) |
Unknown | 8 (6.5) |
Seizure type* | |
Focal aware | 65 (52.8) |
Focal impaired awareness | 36 (29.3) |
Focal to bilateral tonic-clonic | 87 (70.7) |
Other | 0 |
Histopathological diagnosis | |
Astrocytoma | 29 (23.6) |
Oligoastrocytoma | 24 (19.5) |
Oligodendroglioma | 15 (12.2) |
Glioblastoma | 55 (44.7) |
Change to more malignant during follow-up** | 15 (12.2) |
Progression during follow-up *** | 75 (61.0) |
Tumor treatments during follow-up | |
Resection | 108 (87.8) |
Biopsy | 19 (15.4) |
Radiotherapy | 71 (57.7) |
Chemotherapy | 85 (69.1) |
Chemoradiotherapy | 59 (48.0) |
Death during follow-up | |
Yes | 67 (54.5) |
No | 56 (45.5) |
*Several seizure types were possible in the same patient.
**Histopathological verification.
***During treatment leading to a change of treatment or after a stable post-treatment period.